Expired Cans of Salmon From Decades Ago Contained a Huge Surprise
Parasites can reveal a lot about an ecosystem, since they tend to get up in the business of multiple species. But unless they cause a major issue for humans, historically we've mostly ignored them.
That's a problem for parasite ecologists, like Natalie Mastick and Chelsea Wood from the University of Washington, who had been searching for a way to retroactively track the effects of parasites on Pacific Northwestern marine mammals.
So when Wood got a call from Seattle's Seafood Products Association, asking if she'd take boxes of dusty old expired cans of salmon – some dating back to the 1970s – off their hands, her answer was, unequivocally, yes.
Related:
The cans had been set aside for decades as part of the association's quality control process, but in the hands of the ecologists, they became an archive of excellently preserved specimens; not of salmon, but of worms.
While the idea of worms in your canned fish is a bit stomach-turning, these roughly 0.4-inch (1-centimeter) long marine parasites, anisakids, are harmless to humans when killed during the canning process.
"Everyone assumes that worms in your salmon is a sign that things have gone awry," said Wood when the research was published last year.
"But the anisakid life cycle integrates many components of the food web. I see their presence as a signal that the fish on your plate came from a healthy ecosystem."
Anisakids enter the food web when they are eaten by krill, which in turn are eaten by larger species.
This is how anisakids end up in the salmon, and eventually, the intestines of marine mammals, where the worms complete their life cycle by reproducing. Their eggs are excreted into the ocean by the mammal, and the cycle begins again.
"If a host is not present – marine mammals, for example – anisakids can't complete their life cycle and their numbers will drop," said Wood, the paper's senior author.
The 178 tin cans in the 'archive' contained four different salmon species caught in the Gulf of Alaska and Bristol Bay across a 42-year period (1979–2021), including 42 cans of chum (Oncorhynchus keta), 22 coho (Oncorhynchus kisutch), 62 pink (Oncorhynchus gorbuscha), and 52 sockeye (Oncorhynchus nerka).
Although the techniques used to preserve the salmon do not, thankfully, keep the worms in pristine condition, the researchers were able to dissect the filets and calculate the number of worms per gram of salmon.
They found worms had increased over time in chum and pink salmon, but not in sockeye or coho.
"Seeing their numbers rise over time, as we did with pink and chum salmon, indicates that these parasites were able to find all the right hosts and reproduce," said Mastick, the paper's lead author.
"That could indicate a stable or recovering ecosystem, with enough of the right hosts for anisakids."
But it's harder to explain the stable levels of worms in coho and sockeye, especially since the canning process made it difficult to identify the specific species of anisakid.
"Though we are confident in our identification to the family level, we could not identify the [anisakids] we detected at the species level," the authors write.
"So it is possible that parasites of an increasing species tend to infect pink and chum salmon, while parasites of a stable species tend to infect coho and sockeye."
Mastick and colleagues think this novel approach – dusty old cans turned ecological archive – could fuel many more scientific discoveries. It seems they've opened quite a can of worms.
This research was published in Ecology and Evolution.
An earlier version of this article was published in April 2024.
Melting Glaciers Could Reawaken Hundreds of Earth's Volcanoes
Blue Sharks May Be Secret Chameleons, Scientists Discover
Scientists Just Debunked 'Earth's Oldest Impact Crater'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
12 minutes ago
- CBS News
Colorado Parks and Wildlife find invasive zebra mussels in high country
Colorado Parks and Wildlife recently discovered a large group of invasive aquatic animals during a survey. A statement from CPW said they were taking samples in various locations when they discovered multiple zebra mussels in a privately owned body of water in western Eagle County. "This news is a direct result of increased sampling efforts, " said CPW Director Jeff Davis. "This discovery is a significant step toward identifying a potential source of zebra mussels and advancing our efforts for eradication. It would not have been possible without the commitment to protect Colorado's bodies of water by our Aquatic Nuisance Species staff." Zebra mussels are a freshwater mollusk native to Eurasia but have rapidly spread through the United States in the last few decades. According to the USGS, they can be found in the Great Lakes region and the large rivers of the eastern Mississippi drainage, as well as Texas, Colorado, Utah, Nevada and California. CPW has discovered zebra mussel veligers in the Colorado River near New Castle, Mack Mesa at Highline State Park and Highline Lake, where the first adult zebra mussel in the state was found. Veligers are the larval stage of zebra mussels, and were first found in Colorado in 2008. The animals filter out algae that native species need for food and can incapacitate native mussels. Power plants in the U.S. spend millions to keep zebra mussels from clogging water intakes. CPW said they're evaluating the next steps needed to eradicate the mussels. "Understanding the current extent of zebra mussels in western Colorado is a critical step in stopping their spread into new locations," said CPW Invasive Species Program Manager Robert Walters. "Every new detection puts us one step closer to achieving this desired outcome." Officials said good boat hygiene can help control the mussels' spread. They suggested washing boats with warm, soapy water after use and advised boaters and anglers not to transport water from live wells and bait buckets from one body of water to another.


Fox News
an hour ago
- Fox News
Buzz Aldrin commemorates Apollo 11 moon landing milestone on 56th anniversary with heartfelt message
Legendary astronaut Edwin Eugene "Buzz" Aldrin Jr. shared a heartfelt message on the 56th anniversary of the Apollo 11 mission, recalling the historic moment when the lunar module Eagle landed at Tranquility Base. The 95-year-old, who in 1969 walked on the Moon behind mission commander Neil Armstrong, reminisced about the iconic moment they shared while Michael Collins orbited above in the command module. "July 20, 1969. "Contact light, engine stop." The Apollo 11 lunar module Eagle touched down at Tranquility Base on the Moon. A few hours later, Neil Armstrong and I stepped foot on the Moon, with Michael Collins orbiting close-by," Aldrin wrote in a post on X. Aldrin emphasized that this monumental achievement stemmed from years of relentless effort, unwavering dedication, and the teamwork of hundreds of thousands. "An achievement resulting from years of incalculable effort, commitment, and team work." Aldrin invoked President John F. Kennedy's powerful challenge to reach the Moon and see Kennedy's "words become reality." "We choose to go to the Moon in this decade and do the other things, not because they are easy, but because they are hard; because that goal will serve to organize and measure the best of our energies and skills, because that challenge is one that we are willing to accept, one we are unwilling to postpone, and one we intend to win, and the others too," Aldrin wrote, sharing Kennedy's speech he had given at Rice University in September 1962. The speech, delivered to inspire national unity and ambition, set the stage for achieving the decade's most audacious goal. "Well, space is there, and we're going to climb it, and the Moon and the planets are there, and new hopes for knowledge and peace are there. And, therefore, as we set sail we ask God's blessing on the most hazardous and dangerous and greatest adventure on which man has ever embarked," Kennedy's speech concluded, according to the JFK Library. Aldrin closed with a message of pride and gratitude, honoring all who made the mission possible and extending his blessings to the United States and all of humanity. "I couldn't be prouder to have completed this mission with the hundreds of thousands of people that helped get us to the moon and back home. God bless the USA and all of humankind," Aldrin wrote. Aldrin also shared that Pope Leo XIV spoke with him and his wife, expressing how special the moment was. "Anca and I were grateful and touched to receive the highest blessing today, from His Holiness, Pope Leo XIV on the 56th Anniversary of the Apollo 11 moon landing," Aldrin wrote. "What an honor! We prayed for good health, long life, and prosperity for all humankind." The Apollo 11 mission was the first in human history to land men on earth's satellite, fulfilling a dream as old as humanity itself. Armstrong was the first astronaut to step on the lunar surface at 9:56 p.m. ET on July 20, 1969. He was followed 19 minutes later by Aldrin. Aldrin is the only one of the three astronauts on the Apollo 11 mission still alive today. Stepheny Price is a writer for Fox News Digital and Fox Business. She covers topics including missing persons, homicides, national crime cases, illegal immigration, and more. Story tips and ideas can be sent to
Yahoo
2 hours ago
- Yahoo
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile IRVINE, Calif., July 21, 2025--(BUSINESS WIRE)--Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging. Rapid Onset and Sustained Efficacy: Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period. Significant Symptom Relief: Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle. Excellent Safety Profile: No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported. Addressing a Significant Unmet Medical Need Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications. Study Design and Results The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols. Expert Commentary "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. "The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life." "As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004," commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. "The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula." About CBT-004 CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition. Next Steps and Regulatory Strategy Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months. Market Opportunity The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market. About Cloudbreak Pharma Inc. Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law. Please note that the information contained in this press release may not be complete. For further details about Cloudbreak Pharma Inc., and our drug candidates, please refer to our company's website (at View source version on Contacts Contact Information: Cloudbreak Pharma media@ Web: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data